• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Thailand·Healthcare·JSP.BK
Share

JSP Pharmaceutical Manufacturing Stocks

THB 1.67Last Updated 03.11.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

THB 23.75M

THB 1.67
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 2005 and headquartered in Bangkok, Thailand, JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. specializes in providing contract manufacturing services. The company produces a diverse range of products, including dietary supplements, cosmetics, herbal remedies, nutritional products, and pharmaceutical goods within Thailand. Beyond manufacturing, JSP also offers comprehensive support services, encompassing research and development, packaging solutions, and regulatory registration assistance for both pharmaceuticals and dietary supplements. Additionally, the firm manufactures various cleaning products, such as hand sprays and specialized pharmaceutical sanitizers.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of f

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

05.11.2026 02:14

The Dow soared 3% following the Democrats' election victory: this is its best gain in 1.5 years

05.11.2026 01:29

Five tech giants gain $750 bln post-midterms. JPMorgan sees the rally broadening.

05.11.2026 00:54

Shares of defense companies fell following the Democrats' success in the U.S. What happens next?

05.11.2026 00:02

Brent crude falls 10% as Democratic sweep raises hopes for end to Iran war

04.11.2026 23:06

"In the Spotlight": Why Tesla and SpaceX Stocks Are Falling Despite the Market's Uptrend

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026